Tumefactive Demyelinating Lesions in a Patient with Multiple Sclerosis Developed two Days after the Injection of Rituximab

CONCLUSION: Rituximab should be considered as a potential cause of tumefactive demyelinating lesions in patients with MS.PMID:34018172
Source: Acta Neurologica Taiwanica - Category: Neurology Authors: Source Type: research